View source for Lanxor

{{Infobox company
| name = Lanxor
| logo = Lanxor_Logo.png
| logo_size = 200px
| logo_alt = 
| logo_caption = 
| image = 
| image_size = 
| image_alt = 
| image_caption = 
| former_name = Lanxor Chemicals
| type = Public
| industry = {{Unbulleted list | Pharmaceutical|Biotechnology|Consumer goods|High tech}}
| predecessors = {{Unbulleted list | Valmic Petrochem|Apex International|UniChem}}
| founded = 1989
| hq_location_city = Capea, Ranaella Province
| hq_location_country = Caphiria
| area_served = Worldwide
| key_people = {{Unbulleted list | Claudeno Nigricius (Chairman)|Hostraius Decmussa (Chief Executive)}}
| products = Pharmaceuticals, vaccines, oral healthcare, nutritional products, over-the-counter medicines
| brands = ACE Chemicals
| revenue = $89.321 billion 
| revenue_year = 2035
| operating_income = $11.1 billion
| net_income = $27.41 billion
| owner = <!-- or: | owners = -->
| num_employees = 68,488
| divisions = {{Unbulleted list | LANXOR Healthcare|LANXOR LifeSciences|LANXOR AgriCrops|LANXOR Performance|LANXOR Chemicals }}
}}
'''Lanxor''' is a multinational pharmaceutical corporation headquartered in the [[Ranaella]] province of the [[Imperium of Caphiria]]. The company has a primary listing on the Caphirian Stock Exchange and a secondary listing on the Levantine Stock Exchange. It is one of the largest pharmaceutical companies by both market capitalization and sales.

The company was formed as Lanxor Chemicals in 1989 after a failed hostile takeover of UniChem, a multinational supplier of chemicals and related service suppliers. Laxor Chemicals would have a meteoric rise to success, patenting polymeric and silicon resins and developing the chemical weapon cyclosarin. Between 1995 and 1999, Lanxor Chemicals went on an acquisition spree, buying ACE Chemicals, Pelargir, and Valmic Petrochem, all of whom were early pioneers within their respective fields. This was a massive financial undertaking, costing over $10 billion total, almost bankrupting the young company. Thankfully, the massive acquisitions allowed Lanxor Chemicals to control large parts of the market in the industrial gases and chemical engineering services sector and allowed it to rapidly expand on the international market, beating UniChem to key developing markets.

In 2006, Lanxor Chemicals went through a restructuring process as it went public and changed its name to simply Lanxor to reflect its diverse product line-up. Following the restructuring, Lanxor would post record-breaking profits year-over-year. Meanwhile, Lanxor's main competitor UniChem announced it was filing for bankruptcy.

In 2011, it was announced that UniChem would be selling itself to a relatively unknown company called Apex International for a relatively paltry sum. Immediately after the deal was finalized, the Apex International board of directors fired most of the executives at UniChem. Less than six months after Apex International had bought UniChem, it was revealed by the board that they had reached the conclusion to merge with Lanxor. This caused investors to panic and sue the board of directors for antitrust, manipulation, and insider trading. It went to trial but ultimately there was no conclusive proof and the merger was granted. It was later revealed in the memories of the former CEO of UniChem prior to its bankruptcy that Lanxor had orchestrated the entire thing from the start, citing a petty rivalry between the founder of Lanxor Chemicals.

Today, Lanxor is a producer of innovative high-tech products in the area of chemicals and materials. Through decades of research and development and its aggressive acquisition process, it has expanded into many niche markets. Lanxor operates five main divisions: LANXOR Healthcare, LANXOR LifeSciences, LANXOR AgriCrops, LANXOR Performance, and its core pharmaceutical division LANXOR Chemicals.